A heartfelt thanks to all the participants of today's patient event, for the many questions and discussions during the presentations and the lab tours.
A heartfelt thanks to all the participants of today's patient event, for the many questions and discussions during the presentations and the lab tours.
Chemo-refractory #ovariancancer patients' tumors are understudied for several reasons. In the @deciderproject we compared not responding tumors to responsive ones at the DNA, RNA and protein level and discovered interferon pathway as the key.
https://t.co/LYCmuj1buU
Glad to see our chromosomal instability (CIN) signature #ovariancancer paper published in @CD_AACR! We used #WGS data from 640 patient samples from 243 patients enrolled in @deciderproject and characterized the structural variation landscape.
https://t.co/7VNE3KPgoT
Thank you to the entire @deciderproject consortium for the lively discussions, creative ideas, and excellent presentations over the past two days and special thanks to our patient organization representatives from @Syopapotilaat and @gysysuomi.
On the second day of our plenary meeting, we brainstormed and discussed the most exciting and important ideas for implementation in the final year of the @deciderproject. #ovariancancer
On #WorldOvarianCancerDay, learn about the #HorizonEU@deciderproject and its mission to overcome chemotherapy resistance in high-grade serious ovarian cancer.
Discover how DECIDER is making real progress in ovarian cancer research: https://t.co/oHk1bHMIHY
#WOCD2025
Jellyfish visualization tool and the Jellyfisher R package have now been published in OUP Bioinformatics! 🎉 https://t.co/gj1rgS3xaJ #Bioinformatics#DataViz#CancerGenomics (1/7)
Read about the transformative #EUFunded projects 🔸@deciderproject -AI in ovarian cancer
🔸@ERANET_PerMed -personalised medicine
🔸@REMEDi4ALL -repurposing medicines
🔸DISCOVER -translating biomedical research into treatments
in this @CORDIS_EU article👉
https://t.co/upTfNSUJvZ
Are you finishing MSc/PhD and interested in mathematical modeling in cancer? Apply an exciting collaborative project between @HautaniemiLab and @OrionPharma to establish digital twin model based on unique @deciderproject by Jan 10th 2025! #oncosys https://t.co/LF0V7OHJ1p
As part of @PerMedCoE, CORNETO was used to automatize the curation of prior knowledge from Omics to develop cell-level simulation models for personalized medicine. We’re now using it to decipher signaling rewiring linked to ovarian cancer resistance in @deciderproject